Pure Global AI
NCT06049810Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Retreatment Phase III Clinical Trial Evaluating the Efficacy and Safety of Subcutaneous Injection of IBI112 in the Treatment of Moderate to Severe Plaque Psoriasis.
Innovent Biologics (Suzhou) Co. Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
IBI112
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Oct 12, 2023
End date
Dec 31, 2025
Enrollment
550 participants
Primary outcome

Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in
 the treatment of participants with moderate to severe psoriasis

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06049810
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06049810 through Pure Global AI's free database. This Phase 3 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 550 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.